title: ERCC1 Expression in Diffuse Large B-Cell Lymphoma Patients Treated with a Cisplatin-Based Regimen : A Brief Communication.
abstract: There is growing interest in defining biomarkers that could predict response to different chemotherapeutic agents. Excision repair cross complement 1 (ERCC1) enzyme has been shown to predict benefit of cisplatin in different types of cancer. As cisplatin-based regimens are frequently used in the salvage treatment of diffuse large B-cell lymphomas (DLBCL), a small pilot study was conducted to determine whether ERCC1 is expressed in this disease or not. Out of seven patients examined, only one had a 25% ERCC1 expression, which could represent a tumour truly expressing this marker. However, expression was not able to predict response to treatment. It remains unclear whether ERCC1 could serve as a predictive marker for cisplatin in this disease requiring further studies. Key Words : ERCC1 -Large B-cell lymphoma -Cisplatin resistance.
authors.affiliation: The Departments of Medicine, Division of Haematology-Oncology, European Institute of Oncology, Milan, Italy; Medical Oncology, National Cancer Institute, Cairo University, Cairo, Egypt and Pathology, European Institute of Oncology, Milan, Italy.
authors.forename: Hatem A
authors.initials: HA
authors.lastname: Azim
authors.forename: Giancarlo
authors.initials: G
authors.lastname: Pruneri
authors.forename: Paola R
authors.initials: PR
authors.lastname: Raviele
authors.forename: Sara
authors.initials: S
authors.lastname: Steffanoni
authors.forename: Giovanni
authors.initials: G
authors.lastname: Martinelli
authors.forename: Fedro A
authors.initials: FA
authors.lastname: Peccatori